诺和诺德公司成立于1923年，是一家全球领先的生物制药公司，<\/i>总部位于丹麦。立足于在糖尿病领域的百年传承，我们的使命是驱动改变，携手战胜严重慢性疾病。为达成这一目标，我们引领科研突破，扩大公司药物可及性，并致力于预防及最终治愈疾病。诺和诺德在全球80个国家和地区拥有约7.84万名员工，向全球约170个国家和地区提供产品和服务。诺和诺德中国官方网站：http:\/\/www.novonordisk.com.cn<\/a><\/p> \n

\n \n \n \n \n \n \n \n \n \n \n \n
[1] Wilding et al. N Engl J Med. 2021 Mar 18;384(11):989-1002.<\/span><\/p> <\/td> \n <\/tr> \n
[2] Garvey WT, et al. Nat Med. 2022 Oct; 28(10):2083-2091<\/span><\/p> <\/td> \n <\/tr> \n
[3] Rubino D, et al. JAMA. 2021 Apr 13;325(14):1414-1425.<\/span><\/p> <\/td> \n <\/tr> \n
[4] Wadden TA, et al. JAMA. 2021 Apr 13;325(14):1403-1413.<\/span><\/p> <\/td> \n <\/tr> \n
[5] Davies M, et al. Lancet. 2021 Mar 13;397(10278):971-984.<\/span><\/p> <\/td> \n <\/tr> \n
[6] Kadowaki T, et al. Lancet Diabetes Endocrinol. 2022 Mar;10(3):193-206.<\/span><\/p> <\/td> \n <\/tr> \n
[7] Lincoff MA, Brown-Frandson K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221-2232.<\/span><\/p> <\/td> \n <\/tr> \n
[8] Zhao, H., Jia, R. and Leng, A. (2022) 'EPH55 the prevalence of obesity and its implications in China: A narrative review of literature', Value in Health, 25(12). doi:10.1016\/j.jval.2022.09.977.<\/span><\/p> <\/td> \n <\/tr> \n
[9] 中国医疗保健国际交流促进会营养与代谢管理分会,中国营养学会临床营养分会,中华医学会糖尿病学分会,中华医学会肠外肠内营养学分会,中国医师协会营养医师专业委员会,中国超重\/肥胖医学营养治疗指南(2021).中国医学前沿杂志(电子版).2021;13(1):1-55.<\/span><\/p> <\/td> \n <\/tr> \n <\/tbody> \n <\/table> \n<\/div> \n
<\/p> \n
\n<\/div>"]; $("#dvExtra").html(content_array[0]);})();